NASDAQ · PMVP
PMV Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PMVP: Nov 11, 2026
PMV Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.31. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.31 | $-0.25 | $-0.36 | 3 |
| Dec 2026 | $-0.27 | $-0.18 | $-0.36 | 2 |
| Mar 2027 | $-0.26 | $-0.17 | $-0.35 | 2 |
| Jun 2027 | $-0.22 | $-0.17 | $-0.27 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · NASDAQ.com- RTTNews · Oct 28, 3:02 AM EDTCardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial(RTTNews) – Shares of Cardiff Oncology, Inc. (CRDF) fell 5.70% in after-hours trading on Tuesday after the clinical-stage biotechnology company announced Leila Alland's appointment as interim chief medical officer (CMO).
- Zacks · Oct 12, 10:55 AM EDTPMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowPMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
- RTTNews · Oct 2, 3:26 AM EDTBiotech Stocks At 52-Week Highs – KOD, MASS, OBIO, CDNA, PMVP(RTTNews) – The following biotech stocks reached a 52-week high on October 1, 2026, driven by key catalysts such as promising results from clinical trials or revised financial guidance.
- Zacks · Sep 16, 9:55 AM EDTShould You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- RTTNews · Sep 9, 2:41 AM EDTPMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt Filing(RTTNews) – PMV Pharmaceuticals, Inc. (PMVP), a precision oncology company focused on p53-targeting therapies, announced appointment of Philip Herman as Chief Commercial Officer (CCO) to lead commercial strategy and launch preparations for Rezatapopt.
- RTTNews · Sep 1, 1:43 AM EDTPMV Pharma Posts Interim Phase 2 PYNNACLE Ovarian Cancer Data; Prices $50.8 Mln Offering; Stock Down(RTTNews) – PMV Pharmaceuticals, Inc. (PMVP), a precision oncology company, announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating Rezatapopt in TP53 Y220C-mutant advanced solid tumours. Separately, the company pri
- Zacks · Aug 19, 12:00 PM EDTPMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Jun 24, 12:00 PM EDTPMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's WhyPMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Jun 10, 9:35 AM EDTPMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerPMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- RTTNews · Mar 9, 5:15 AM EDTPMV Pharma Targets Q1'27 NDA Filing For Rezatapopt In Platinum-Resistant Ovarian Cancer(RTTNews) – PMV Pharmaceuticals, Inc. (PMVP), a clinical-stage oncology company, reported financial results for the full year 2025 and provided details of the milestones ahead for its lead drug candidate, Rezatapopt.
- RTTNews · Sep 10, 9:01 AM EDTPMV Pharma Reports Positive Interim Data From Phase 2 PYNNACLE Study(RTTNews) – PMV Pharmaceuticals, Inc. (PMVP) Wednesday announced positive interim data from the Phase 2 portion of Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors.
- NASDAQ.com · Sep 10, 8:28 AM EDTPre-Market Most Active for Sep 10, 2025 : CAMP, NIO, PMVP, NVDA, OPEN, TSLL, ORCL, PL, SQQQ, JOBY, SAN, GMEThe NASDAQ 100 Pre-Market Indicator is up 141.13 to 23,980.93. The total Pre-Market volume is currently 120,438,787 shares traded.The following are the most active stocks for the pre-market session: CAMP4 Therapeutics Corporation (CAMP) is +1.89 at $3.88, with 20,785,300 shares
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for PMV Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.